In 2021, vaccine giant Merca East opened its year with a cold splash of cold water on the development of a "crazy" new crown vaccine.
January 25th, Mercedon will stop developing two candidate vaccines V590 and V591 for SARS-CoV-2/COVID-19.
The main reason for this is that a review of the results of the Clinical Study of Phase 1 of the vaccine by Mercadon found that although both V590 and V591 in the study showed good tolerance, their immune responses were lower than those of the immune response after natural infection and those of other SARS-CoV-2/COVID-19 vaccines.
Despite several crises in the development of new crown vaccines by multinational pharmaceutical giants, such as AstraZeneca and Oxford University, which were suspended for seven weeks in trials in the United States, Pfizer is now facing a shortage of capacity, and Pfizer has experienced a number of adverse reactions since its approval. Society has also been talking about its safety; the Modena vaccine has also had cases of severe allergies; in December 2020, Sanofi and GlaxoSmithKline delayed the start of phase III trials because of inadequate immune responses in older patients in their clinical trials... But Mercadon was also the first multinational drug giant to announce a halt to vaccine research and development.
's three big plans for post-01 entry are relatively unusual for Mercedon, which entered the race for the new crown vaccine later.
In May 2020, Mercadon announced three major plans to fight the new coronavirus, including the acquisition of Themis Bioscience, which focuses on vaccines and immunomodulation therapies for infectious diseases, including neo-coronary pneumonia, and the development of the new coronary pneumonia oral antiviral drug EIDD-2801 in collaboration with IAVI.
in the development of the new crown vaccine, the time and progress of research and development has been "backwards".
at the time, Reuters reported that more than 100 vaccines for new crown pneumonia were under development when Mercedon acquired Themis, 12 of which were being tested in humans to assess their safety.
the plan, Mercadon's new crown vaccine V591 entered Phase 1 clinical in the third quarter of 2020, with a total of 300 healthy volunteers in 2 Phase 1 trials.
of its immune properties by the end of 2020.
V590 entered clinical Phase 1 trial a few weeks later than V591.
now, several new crown vaccines are on the market around the world.
's attitude to the new crown vaccine research and development competition is also quite clear.
On May 27, 2020, the Financial Times reported that Kenneth Frazier, chief executive of Mercedon, questioned the time frame for developing an effective new coronavirus vaccine in 12 to 18 months, describing the much-discussed schedule as "very radical".
02 new crown drug research and development in the world has exceeded 100 million people, in addition to vaccines, people need more hope.
now, Mercado still has hope of taking a piece of the market in the fight against new crown pneumonia, its third plan: the development of new crown drugs.
now that the two current plans have failed, Mr Mercedon's third seems to be going well.
he had thought of a "one-in-one solution" since he joined the new crown vaccine competition? It is understood that The new coronary pneumonia oral antiviral drug EIDD-2801 (MK-4482), developed in collaboration with Ridgeback Bio, is a powerful nucleoside analogogen research oral biology The preparation, which inhibits the replication of a variety of RNA viruses, including SARS-CoV-2 (the pathogenic factor of SARS-CoV-2, COVID-19), is considered an "oral Redsyvir-like drug".
is understood to be able to play a role in coronaviruses that are already resistant to Redsivirus.
In November 2020, Roger Perlmutter, head of drug research and development at Mercator, revealed that from the clinical phase 1 few subjects and the current phase 2 progress, the drug five-day course of resistance is good, one-day secondary medication far enough to suppress the concentration of virus replication, or basically remove the virus.
EIDD-2801 is currently undergoing Phase 2/3 clinical trials, which are expected to be completed by May this year.
is expected to receive preliminary efficacy data in the first quarter of 2021 and plans to make them public if clinically significant.
if successful, this could be the first oral new coronary treatment, allowing patients to be treated outside the hospital.
's move doesn't stop there in the development of new crown drugs.
On November 23, 2020, Mercado announced that it would acquire Anko Immune Growth Inc.'s clinical program to fight the new crown, and that Mercado would acquire all outstanding shares of Anko Immunity through a subsidiary, with an advance cash payment of $425 million.
and Mercedon will inject $50m into the new company to become a minority shareholder when the acquisition is completed.
Anke immunity's main product is CD24Fc, the world's first innovative drug for recombinant fusion protein for the congenital immune system, mainly used to treat patients with severe and critical new coronary pneumonia, is an important expansion of Merca East's anti-neo crown research and development pipeline. According to the interim analysis data of the
Anko Immunization Report, patients with severe and critically ill neo-coronary pneumonia were treated with a single dose of CD24Fc, with a 60 percent increased chance of clinical improvement and a more than 50 percent lower risk of death or respiratory failure than those receiving a placebo.
December 23, 2020, Mercadon announced that it had reached an agreement with the U.S. government to support the development, production and initial supply of a biopharmace technology (CD24Fc, to be named MK-7110) that is currently under clinical trial, after obtaining FDA approval or emergency use authorization (EUA).
under the agreement, Mercedon will receive support of approximately $356 million through June 30, 2021, and will produce and supply approximately 60,000 to 100,000 doses of MK-7110 to the U.S. government to help the government achieve its Operation Warp Speed goal.
, Mercadon is investing in expanding production and enhancing the supply capacity of the MK-7110.
03 New Crown Drug Research and Development is of great significance to Mercadon's ability to get back to the next game in the development of New Crown Drug.
2020, Mercadon's share price fell 12 per cent and its market capitalisation lost $24.6bn, almost as much as K's two-year sales, according to Evaluate Pharma.
Evaluate Pharma had forecast total sales of its star drug, K, to reach $14.39 billion by 2020.
2019, K-Drug's global sales were $11.1 billion.
china is the most important market in the world.
2019, Merca East's annual sales were $46.8 billion, up 13% year-on-year (fixed exchange rate).
year-on-year growth rate in China was much higher than its global growth rate of 58 per cent.
, however, its performance in the Chinese market remains fraught with variables.
products, in 2020 Merca East in China a total of 7 new products and adaptation certificates were approved, the specific sales volume will take time.
Its once-heavy products such as finasteride, simvastatin, potassium chlorsatum, and Monrust sodium chewing tablets have not been collected, while star product K medicine has not been successful in the 2020 national health care negotiations, and investors at the JPM conference are still concerned about the response of Mercadon after the expiration of its K drug patent... In management, on January 6th, Merca East announced a top-level restructuring of the Chinese organization, and peng Leili, the current general manager of the vaccine division, will leave office in April this year, and Merca East China has appointed Tang Xiaochun to take over as head of the vaccine division, and Tang Xiaochun is currently the head of the Global Medical Affairs Team of Mercedong Oncology in China.
it remains to be seen whether 2021 Mercedon will be able to turn things around on the new crown drug and continue to thrive in the Chinese market.